Kimia Biosciences Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Kimia Biosciences's earnings have been declining at an average annual rate of -61.9%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 1.1% per year.
Key information
-61.9%
Earnings growth rate
-68.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 1.1% |
| Return on equity | -350.8% |
| Net Margin | -1.1% |
| Next Earnings Update | 11 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Kimia Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,030 | -12 | 146 | 0 |
| 31 Mar 24 | 1,049 | -53 | 152 | 0 |
| 31 Dec 23 | 972 | -133 | 183 | 0 |
| 30 Sep 23 | 999 | -148 | 184 | 0 |
| 30 Jun 23 | 1,162 | -132 | 165 | 0 |
| 31 Mar 23 | 1,285 | -94 | 181 | 0 |
| 31 Dec 22 | 1,357 | -46 | 160 | 0 |
| 30 Sep 22 | 1,402 | -25 | 173 | 0 |
| 30 Jun 22 | 1,306 | -29 | 153 | 0 |
| 31 Mar 22 | 1,249 | -37 | 158 | 0 |
| 31 Dec 21 | 1,310 | -32 | 166 | 0 |
| 30 Sep 21 | 1,322 | -14 | 165 | 0 |
| 30 Jun 21 | 1,387 | 34 | 148 | 0 |
| 31 Mar 21 | 1,327 | 51 | 155 | 0 |
| 31 Dec 20 | 1,180 | 52 | 144 | 0 |
| 30 Sep 20 | 1,110 | 49 | 134 | 0 |
| 30 Jun 20 | 1,055 | 30 | 114 | 0 |
| 31 Mar 20 | 1,063 | 14 | 120 | 0 |
| 31 Dec 19 | 1,039 | 21 | 110 | 0 |
| 30 Sep 19 | 967 | 40 | 107 | 0 |
| 30 Jun 19 | 973 | 38 | 93 | 0 |
| 31 Mar 19 | 939 | 39 | 97 | 0 |
| 31 Dec 18 | 754 | 58 | 55 | 0 |
| 30 Sep 18 | 790 | 50 | 51 | 0 |
| 30 Jun 18 | 793 | 59 | 53 | 0 |
| 31 Mar 18 | 763 | 17 | 84 | 0 |
| 31 Dec 17 | 425 | 33 | 32 | 0 |
| 30 Sep 17 | 186 | 8 | 21 | 0 |
| 30 Jun 17 | 30 | -13 | 12 | 0 |
| 31 Mar 17 | 15 | -9 | 8 | 0 |
| 31 Dec 16 | 5 | -21 | 8 | 0 |
| 30 Sep 16 | 5 | -26 | 12 | 0 |
| 30 Jun 16 | 1 | -29 | 16 | 0 |
| 31 Mar 16 | 2 | -41 | 22 | 0 |
| 30 Sep 15 | 14 | -24 | 21 | 0 |
| 30 Jun 15 | 17 | -23 | 20 | 0 |
| 31 Mar 15 | 17 | -17 | 20 | 0 |
| 31 Dec 14 | 24 | -23 | 24 | 0 |
| 30 Sep 14 | 33 | -20 | 25 | 0 |
| 30 Jun 14 | 44 | -14 | 30 | 0 |
| 31 Mar 14 | 64 | -8 | 30 | 0 |
| 31 Dec 13 | 85 | 5 | 29 | 0 |
Quality Earnings: 530313 is currently unprofitable.
Growing Profit Margin: 530313 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 530313 is unprofitable, and losses have increased over the past 5 years at a rate of 61.9% per year.
Accelerating Growth: Unable to compare 530313's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 530313 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.5%).
Return on Equity
High ROE: 530313 has a negative Return on Equity (-350.82%), as it is currently unprofitable.